Company profile MGTX
After 39 days of this quarter the interest is at 78.0. Based on that we can calculate that during remaining 52 days it will total up to 182.0. MeiraGTx Holdings expected interest is significantly higher compared to same quarter last year (+550.0%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 97 | 209 115.5% QoQ | 271 29.7% QoQ | 36 -86.7% QoQ |
| 2020 | 165 70.1% YoY 358.3% QoQ | 45 -78.5% YoY -72.7% QoQ | 198 -26.9% YoY 340.0% QoQ | 101 180.6% YoY -49.0% QoQ |
| 2021 | 94 -43.0% YoY -6.9% QoQ | 105 133.3% YoY 11.7% QoQ | 61 -69.2% YoY -41.9% QoQ | 203 101.0% YoY 232.8% QoQ |
| 2022 | 139 47.9% YoY -31.5% QoQ | 88 -16.2% YoY -36.7% QoQ | 280 359.0% YoY 218.2% QoQ | 146 -28.1% YoY -47.9% QoQ |
| 2023 | 28 -79.9% YoY -80.8% QoQ | 88 0.0% YoY 214.3% QoQ | 143 -48.9% YoY 62.5% QoQ | 142 -2.7% YoY -0.7% QoQ |
| 2024 | 78 178.6% YoY -45.1% QoQ | - | - | - |
The average 5 years interest of MeiraGTx Holdings was 10.41 per week. The last year interest of MeiraGTx Holdings compared to the last 5 years has changed by -11.53%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -31.78%.
There is not enough data for MeiraGTx Holdings gene therapy to provide analysis
There is not enough data for MeiraGTx Holdings gene therapy to provide correlation calculation
There is not enough data for MeiraGTx Holdings gene therapy to provide analysis
There is not enough data for inherited retinal diseases treatment to provide analysis
There is not enough data for inherited retinal diseases treatment to provide correlation calculation
There is not enough data for inherited retinal diseases treatment to provide analysis
There is not enough data for large degenerative ocular diseases treatment to provide analysis
There is not enough data for large degenerative ocular diseases treatment to provide correlation calculation
There is not enough data for large degenerative ocular diseases treatment to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. neurodegenerative diseases treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 45 | 147 226.7% QoQ | 80 -45.6% QoQ | 126 57.5% QoQ |
| 2020 | 71 57.8% YoY -43.7% QoQ | 64 -56.5% YoY -9.9% QoQ | 64 -20.0% YoY 0.0% QoQ | 104 -17.5% YoY 62.5% QoQ |
| 2021 | 126 77.5% YoY 21.2% QoQ | 149 132.8% YoY 18.3% QoQ | 0 -100.0% YoY -100.0% QoQ | 140 34.6% YoY inf% QoQ |
| 2022 | 203 61.1% YoY 45.0% QoQ | 30 -79.9% YoY -85.2% QoQ | 239 inf% YoY 696.7% QoQ | 74 -47.1% YoY -69.0% QoQ |
| 2023 | 134 -34.0% YoY 81.1% QoQ | 59 96.7% YoY -56.0% QoQ | 122 -49.0% YoY 106.8% QoQ | 66 -10.8% YoY -45.9% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of neurodegenerative diseases treatment was 7.83 per week. The last year interest of neurodegenerative diseases treatment compared to the last 5 years has changed by -32.18%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -35.32%.
After 39 days of this quarter the interest is at 145.0. Based on that we can calculate that during remaining 52 days it will total up to 338.0. xerostomia treatment expected interest is significantly higher compared to previous quarter (+64.9%) and same quarter last year (+85.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 194 | 137 -29.4% QoQ | 214 56.2% QoQ | 228 6.5% QoQ |
| 2020 | 312 60.8% YoY 36.8% QoQ | 178 29.9% YoY -42.9% QoQ | 280 30.8% YoY 57.3% QoQ | 216 -5.3% YoY -22.9% QoQ |
| 2021 | 162 -48.1% YoY -25.0% QoQ | 230 29.2% YoY 42.0% QoQ | 80 -71.4% YoY -65.2% QoQ | 113 -47.7% YoY 41.2% QoQ |
| 2022 | 230 42.0% YoY 103.5% QoQ | 224 -2.6% YoY -2.6% QoQ | 258 222.5% YoY 15.2% QoQ | 254 124.8% YoY -1.6% QoQ |
| 2023 | 182 -20.9% YoY -28.3% QoQ | 123 -45.1% YoY -32.4% QoQ | 142 -45.0% YoY 15.4% QoQ | 205 -19.3% YoY 44.4% QoQ |
| 2024 | 145 -20.3% YoY -29.3% QoQ | - | - | - |
The average 5 years interest of xerostomia treatment was 15.74 per week. The last year interest of xerostomia treatment compared to the last 5 years has changed by -9.72%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -16.21%.
There is not enough data for achromatopsia treatment to provide analysis
There is not enough data for achromatopsia treatment to provide correlation calculation
There is not enough data for achromatopsia treatment to provide analysis
Google Trends for X-linked retinitis pigmentosa treatment
Not enough data for reliable calculations!
There is not enough data for X-linked retinitis pigmentosa treatment to provide analysis
There is not enough data for X-linked retinitis pigmentosa treatment to provide correlation calculation
There is not enough data for X-linked retinitis pigmentosa treatment to provide analysis
There is not enough data for RPE65-deficiency treatment to provide analysis
There is not enough data for RPE65-deficiency treatment to provide correlation calculation
There is not enough data for RPE65-deficiency treatment to provide analysis
There is not enough data for radiation-induced xerostomia clinical trials to provide analysis
There is not enough data for radiation-induced xerostomia clinical trials to provide correlation calculation
There is not enough data for radiation-induced xerostomia clinical trials to provide analysis
After 39 days of this quarter the interest is at 103.0. Based on that we can calculate that during remaining 52 days it will total up to 240.0. Parkinson's gene therapy expected interest is significantly higher compared to previous quarter (+238.0%) and same quarter last year (+421.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 166 | 27 -83.7% QoQ | 31 14.8% QoQ | 83 167.7% QoQ |
| 2020 | 105 -36.7% YoY 26.5% QoQ | 24 -11.1% YoY -77.1% QoQ | 279 800.0% YoY 1062.5% QoQ | 173 108.4% YoY -38.0% QoQ |
| 2021 | 32 -69.5% YoY -81.5% QoQ | 110 358.3% YoY 243.8% QoQ | 177 -36.6% YoY 60.9% QoQ | 168 -2.9% YoY -5.1% QoQ |
| 2022 | 182 468.8% YoY 8.3% QoQ | 59 -46.4% YoY -67.6% QoQ | 113 -36.2% YoY 91.5% QoQ | 48 -71.4% YoY -57.5% QoQ |
| 2023 | 46 -74.7% YoY -4.2% QoQ | 66 11.9% YoY 43.5% QoQ | 0 -100.0% YoY -100.0% QoQ | 71 47.9% YoY inf% QoQ |
| 2024 | 103 123.9% YoY 45.1% QoQ | - | - | - |
The average 5 years interest of Parkinson's gene therapy was 7.9 per week. The last year interest of Parkinson's gene therapy compared to the last 5 years has changed by -41.52%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -28.04%.
There is not enough data for MeiraGTx Holdings collaboration with Janssen Pharmaceuticals to provide analysis
There is not enough data for MeiraGTx Holdings collaboration with Janssen Pharmaceuticals to provide correlation calculation
There is not enough data for MeiraGTx Holdings collaboration with Janssen Pharmaceuticals to provide analysis